Drug Profile
Research programme: RNAi therapeutics - Sirna Therapeutics/Eli Lilly and Company
Latest Information Update: 08 Jan 2008
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Sirna Therapeutics
- Class Small interfering RNA
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
- 03 Feb 2004 Preclinical trials in Cancer in USA (unspecified route)